Do Oncologists Believe New Cancer Drugs Offer Good Value?
- 1 February 2006
- journal article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 11 (2), 90-95
- https://doi.org/10.1634/theoncologist.11-2-90
Abstract
Learning Objectives: After completing this course, the reader will be able to: Describe how academic oncologists view the costs of new treatments in their treatment recommendations.Discuss academic oncologists’ perceptions of the cost and benefit of one new treatment in light of published results.Describe how academic oncologists view the cost-effectiveness of new treatments relative to previously accepted standards. CME Access and take the CME test online and receive 1 AMA PRA category 1 credit at CME.TheOncologist.comKeywords
This publication has 13 references indexed in Scilit:
- The Price Tag on Progress — Chemotherapy for Colorectal CancerNew England Journal of Medicine, 2004
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Incremental and average cost-effectiveness ratios: will physicians make a distinction?Risk Analysis, 2003
- Outpatient cancer drug costsCancer, 2002
- The Sad History Of Health Care Cost Containment As Told In One ChartHealth Affairs, 2002
- Health Spending Growth Up In 1999; Faster Growth Expected In The FutureHealth Affairs, 2001
- US neurologistsNeurology, 2000
- Systematic Overview of Cost-Utility Assessments in OncologyJournal of Clinical Oncology, 2000
- Are Pharmaceuticals Cost-Effective? A Review Of The EvidenceHealth Affairs, 2000
- Public Preferences for Prevention versus Cure: What if an Ounce of Prevention is Worth Only an Ounce of Cure?Medical Decision Making, 1998